Form 4: Thermo Fisher Scientific CEO Marc Casper Executes Stock Options and Sells Shares Under 10b5-1 Plan

Thermo Fisher Scientific's CEO, Marc N. Casper, exercised stock options and sold shares of common stock on April 29 and 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 29 and 30, 2024, Marc N. Casper, the Chairman and CEO of Thermo Fisher Scientific, executed stock options to acquire 10,000 shares on each day at a price of $190.59 per share.
• Following the exercise of these options, Casper sold shares of Thermo Fisher Scientific common stock on the open market.
• The sales on April 29, 2024, involved multiple transactions at weighted average prices ranging from $571.77 to $579.22.
• Similarly, on April 30, 2024, shares were sold at weighted average prices ranging from $568.88 to $576.08.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 10, 2023.
• After these transactions, Casper directly owns 123,816.462 shares of Thermo Fisher Scientific common stock.
• He also indirectly owns 11,300 shares through the Alison Casper 2020 Irrevocable Trust, 43,608 shares through Floral Park Associates, Inc., and 5,000 shares through the MNC 2020 Irrevocable Trust.
• Following the reported transactions, Casper directly holds 36,300 stock options.

Sentiment

Score: 5

Explanation: The document reflects routine transactions under a pre-existing trading plan, indicating a neutral sentiment. It doesn't suggest any particular positive or negative outlook for the company.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. The use of Rule 10b5-1 plans allows insiders to sell shares over a period of time, mitigating concerns about trading on non-public information. Investors often monitor these transactions for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Executive compensation practices, including stock options and sales, are common across the S&P 500.
• Companies like Danaher and Agilent Technologies also have executives who utilize 10b5-1 trading plans.
• The size and frequency of these transactions are generally in line with industry norms for companies of Thermo Fisher Scientific's size and market capitalization.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• However, the pre-planned nature of the sales mitigates concerns about insider information influencing the transactions.

Key Dates